Literature DB >> 30590840

RECOMMENDATIONS FOR MONITORING AND INTERNAL DOSIMETRY FOR NUCLEAR MEDICINE STAFF EXPOSED TO RADIOPHARMACEUTICALS 223Ra DICHLORIDE.

Dominique Saurat1, Olivier Aupée2, Eric Gontier3, Denis Métivier1, Alain Cazoulat1, Yannick Lecompte1.   

Abstract

223Ra is a radiopharmaceutical used as unsealed source in nuclear medicine. In the case of staff inhalation contamination of 223Ra, methods to estimate the committed effective dose should be chosen with care. Three methods are available: whole-body measurement and gamma spectrometry for urine or faeces samples. Considering the analytical performances and uncertainties of these three methods, we propose recommendations for special dose assessment. As a first choice, due to its rapidity and its non-invasiveness, an in vivo analysis (with HPGe detector) is the most appropriate method. However, after 24 h, whole-body counting is not sensitive enough to detect a minimum effective dose of 1 mSv. Sufficient sensitivity can only be reached up to 8 days after contamination by true 24 h faeces samples analyses. Thus, despite its main drawbacks, this method appears to be more appropriate than urine to estimate the committed effective dose in addition to whole-body counting.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30590840     DOI: 10.1093/rpd/ncy065

Source DB:  PubMed          Journal:  Radiat Prot Dosimetry        ISSN: 0144-8420            Impact factor:   0.972


  1 in total

1.  Radiobiological effects of the alpha emitter Ra-223 on tumor cells.

Authors:  Kristina Bannik; Balázs Madas; Marco Jarzombek; Andreas Sutter; Gerhard Siemeister; Dominik Mumberg; Sabine Zitzmann-Kolbe
Journal:  Sci Rep       Date:  2019-12-06       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.